{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:38:02Z","timestamp":1715733482989},"posted":{"date-parts":[[2024]]},"group-title":"SSRN","reference-count":38,"publisher":"Elsevier BV","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.2139\/ssrn.4815832","type":"posted-content","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T19:35:43Z","timestamp":1715715343000},"source":"Crossref","is-referenced-by-count":0,"title":["Predicting Vte and Utility of Thromboprophylaxis in Metastatic and Recurrent Cervical Cancer"],"prefix":"10.2139","author":[{"given":"Christopher  A.","family":"Walker","sequence":"first","affiliation":[]},{"given":"Carson","family":"Edwards","sequence":"additional","affiliation":[]},{"given":"Don","family":"McIntire","sequence":"additional","affiliation":[]},{"given":"Lydia","family":"Makepeace","sequence":"additional","affiliation":[]},{"given":"Steven B.","family":"Holloway","sequence":"additional","affiliation":[]},{"given":"Ev","family":"Kakadiaris","sequence":"additional","affiliation":[]},{"given":"Alexandra","family":"Spirtos","sequence":"additional","affiliation":[]},{"given":"David  Scott","family":"Miller","sequence":"additional","affiliation":[]},{"given":"Jayanthi","family":"Lea","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"13","key":"ref1","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2017-03-743211","article-title":"Cancer-associated pathways and biomarkers of venous thrombosis","volume":"130","author":"Y Hisada","year":"2017","journal-title":"Blood"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"A A Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"A A Khorana","year":"2008","journal-title":"Blood"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1055\/s-0037-1613051","article-title":"Venous thrombosis in patients with solid tumors: determination of frequency and characteristics","volume":"87","author":"S Sallah","year":"2002","journal-title":"Thromb Haemost"},{"issue":"4","key":"ref5","article-title":"Incidence of Venous Thromboembolism and Its Effect on Survival Among Patients With Common Cancers","volume":"166","author":"H K Chew","year":"2006","journal-title":"Arch Intern Med"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1002\/cncr.21496","article-title":"Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study: Risk Factors for Thrombosis with Chemotherapy","volume":"104","author":"A A Khorana","year":"2005","journal-title":"Cancer"},{"issue":"16","key":"ref7","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1200\/JCO.2008.16.1109","article-title":"Incidence of Venous Thromboembolism in Patients With Ovarian Cancer Undergoing Platinum\/Paclitaxel-Containing First-Line Chemotherapy: An Exploratory Analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group","volume":"26","author":"C Fotopoulou","year":"2008","journal-title":"JCO"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.thromres.2013.01.027","article-title":"Incidence of venous thromboembolism before treatment in cervical cancer and the impact of management on venous thromboembolism after commencement of treatment","volume":"131","author":"T Satoh","year":"2013","journal-title":"Thrombosis Research"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ygyno.2016.06.012","article-title":"Significance of venous thromboembolism in women with cervical cancer","volume":"142","author":"K Matsuo","year":"2016","journal-title":"Gynecologic Oncology"},{"issue":"10","key":"ref10","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/cncr.23062","article-title":"Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients","volume":"110","author":"A A Khorana","year":"2007","journal-title":"Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.thromres.2023.04.015","article-title":"Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial","volume":"226","author":"N Potere","year":"2023","journal-title":"Thrombosis Research"},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/cncr.20893","article-title":"Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine","volume":"103","author":"G Numico","year":"2005","journal-title":"Cancer"},{"issue":"35","key":"ref13","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.2012.42.4358","article-title":"Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis","volume":"30","author":"S Seng","year":"2012","journal-title":"JCO"},{"issue":"25","key":"ref14","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","article-title":"High Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective Analysis","volume":"29","author":"R A Moore","year":"2011","journal-title":"JCO"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.medj.2021.02.002","article-title":"Increased incidence of venous thromboembolism with cancer immunotherapy","volume":"2","author":"J Roopkumar","year":"2021","journal-title":"Med"},{"issue":"28","key":"ref16","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","article-title":"Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study","volume":"27","author":"B J Monk","year":"2009","journal-title":"JCO"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"31607","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"K S Tewari","year":"2017","journal-title":"The Lancet"},{"issue":"20","key":"ref18","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer","volume":"385","author":"N Colombo","year":"2021","journal-title":"N Engl J Med"},{"issue":"24","key":"ref19","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"C Ay","year":"2010","journal-title":"Blood"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score","volume":"7","author":"M Verso","year":"2012","journal-title":"Intern Emerg Med"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","article-title":"A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study","volume":"22","author":"G T Gerotziafas","year":"2017","journal-title":"The Oncologist"},{"key":"ref22","doi-asserted-by":"crossref","DOI":"10.1016\/j.gore.2023.101156","article-title":"Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancer","volume":"46","author":"R N Piver","year":"2023","journal-title":"Gynecologic Oncology Reports"},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.1016\/S0090-8258(21)01200-2","article-title":"The clinical utility of the Khorana score in determining risk for venous thromboembolism in patients with gynecologic cancer","volume":"162","author":"A Apple","year":"2021","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/bloodadvances.2021005590","article-title":"The incidence of cancer-associated thrombosis is increasing over time","volume":"6","author":"A Mahajan","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/gyno.2001.6452","article-title":"The Clinical Course of Deep Vein Thrombosis in Patients with Gynecologic Cancer","volume":"84","author":"M A Morgan","year":"2002","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"A A Khorana","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S1470-2045(07)70409-6","article-title":"Venous thromboembolism in cervical cancer","volume":"9","author":"L Barbera","year":"2008","journal-title":"The Lancet Oncology"},{"issue":"13","key":"ref28","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1200\/JCO.2010.32.3220","article-title":"Venous Thromboembolic Events With Chemotherapy Plus Bevacizumab: A Pooled Analysis of Patients in Randomized Phase II and III Studies","volume":"29","author":"H I Hurwitz","year":"2011","journal-title":"JCO"},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.27772","article-title":"Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States: VTE in Ambulatory US Cancer Patients","volume":"119","author":"A A Khorana","year":"2008","journal-title":"Cancer"},{"issue":"18","key":"ref30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184603","article-title":"Risk of Thrombo-Embolic Events in Ovarian Cancer: Does Bevacizumab Tilt the Scale? A Systematic Review and Meta-Analysis","volume":"13","author":"M Saerens","year":"2021","journal-title":"Cancers"},{"issue":"14","key":"ref31","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"F I Mulder","year":"2021","journal-title":"Blood"},{"issue":"16","key":"ref32","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer","volume":"41","author":"N S Key","year":"2023","journal-title":"JCO"},{"issue":"Supplement_1","key":"ref33","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2019-128831","article-title":"Bleeding Risk in a Cohort of Ambulatory Cancer Patients Receiving Outpatient Prophylactic Anticoagulation for Venous Thrombosis Prevention","volume":"134","author":"A B Wilks","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"ref34","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1182\/blood-2019-127917","article-title":"Meta-Analysis and Cost-Effectiveness Analysis of Low-Dose Direct Oral Anticoagulant for the Prevention of Cancer Associated Thrombosis","volume":"134","author":"A Li","year":"2019","journal-title":"Blood"},{"issue":"8","key":"ref35","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/cncr.32724","article-title":"Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States","volume":"126","author":"A Li","year":"2020","journal-title":"Cancer"},{"issue":"20","key":"ref36","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1182\/bloodadvances.2020003115","article-title":"Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis","volume":"4","author":"Ftm Bosch","year":"2020","journal-title":"Blood Advances"},{"issue":"2","key":"ref37","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1160\/TH16-08-0615","article-title":"Cancer-associated venous thromboembolism: Burden, mechanisms, and management","volume":"117","author":"C Ay","year":"2017","journal-title":"Thromb Haemost"},{"issue":"1","key":"ref38","article-title":"Thrombogenesis-associated genetic determinants as predictors of thromboembolism and prognosis in cervical cancer","volume":"13","author":"B V Neto","year":"2023","journal-title":"Sci Rep"}],"container-title":[],"original-title":[],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T22:08:39Z","timestamp":1715724519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ssrn.com\/abstract=4815832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":38,"URL":"https:\/\/doi.org\/10.2139\/ssrn.4815832","relation":{},"subject":[],"published":{"date-parts":[[2024]]},"subtype":"preprint"}}